<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00682695</url>
  </required_header>
  <id_info>
    <org_study_id>R01NS036695</org_study_id>
    <nct_id>NCT00682695</nct_id>
  </id_info>
  <brief_title>Genetic and Environmental Risk Factors for Hemorrhagic Stroke</brief_title>
  <acronym>GERFHS</acronym>
  <official_title>Genetic and Environmental Risk Factors for Hemorrhagic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University, Durham, NC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find risk factors for hemorrhagic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed research builds on the most robust, statistically significant and replicated
      association identified to determine the mechanism by which it may relate to ICH risk. Given
      that ICH is an extreme phenotype on a spectrum of manifestations of cerebral small vessel
      disease, the findings that emerge from our proposed studies offer the promise of broad impact
      for research and treatment in a wide variety of cerebrovascular disorders.

      In the genetic epidemiology of hemorrhagic stroke, we propose to perform an in-depth
      fine-mapping of the entire 1q22 genomic region (~250kb) to investigate whether genetic
      variants influence gene expression that correlates with ICH status or changes in expression
      over time in ICH cases. As existing samples were not processed for gene expression analysis,
      we will recruit 500 non-lobar ICH cases (~150 black, ~350 white) and 1000 controls (300
      black, 700 white) to correlate sequence variation with gene expression levels in the same
      samples. Identified associations will be replicated in 6,000 cases of ICH and 9,361
      individuals in the CHARGE consortium with MRI white matter hyperintensity volume measurements
      and 5,000 controls. The current proposal takes the next logical step by pursuing the most
      promising findings of our GWAS to complete the following aims:

      Specific Aim #1: Perform deep DNA sequencing of Chr 1q22 among non-Hispanic white and black
      ICH cases and controls to identify all genomic variation within these regions and test the
      following:

      Hypothesis #1a: Variants strongly associated with ICH risk at 1q22 are either directly causal
      or in linkage disequilibrium to causal variants that influence ICH risk, and sequencing of
      these regions will reveal both common and rare variants that exert this causal influence.

      Hypothesis #1b: Variants strongly associated with ICH risk at 1q22 will be associated with
      risk of, or severity of, leukoaraiosis.

      Specific Aim #2: Prospectively collect DNA, RNA, and serum on ICH cases and geographic region
      site-specific controls both at the time of ICH and in the convalescent period. We will
      perform RNA expression profiling between cases and controls and over time in cases. We will
      compute expression quantitative trait locus (eQTL) analysis with SNPs arising from Aim 1. We
      will also determine whether alternatively spliced transcripts differ between cases and
      controls.

      Hypothesis #2a: Variation in gene expression or alternatively spliced transcripts affects
      risk of ICH.

      Hypothesis #2b: Variations identified by DNA sequencing will affect gene expression and/or
      alternatively spliced transcripts that affect risk of ICH.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 1997</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Perform deep DNA sequencing of Chr 1q22 among non-Hispanic white and black ICH cases and controls to identify all genomic variation within these regions.</measure>
    <time_frame>Ongoing to be completed at the end of June 2021</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collect and analyze DNA, RNA, and serum on ICH cases and geographic region site-specific controls both at the time of ICH and in the convalescent period. We will perform RNA expression profiling between cases and controls and over time in cases.</measure>
    <time_frame>Ongoing to be completed at the end of June 2021</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Healthy volunteers and people who have had a hemorrhagic stroke and live within University of Maryland, University of Cincinnati, Massachusetts General Hospital and Duke University area</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood DNA, RNA and CBA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be limited to physician-reviewed cases of people who have had a hemorrhagic
        stroke and who live within a 50-mile radius of Cincinnati, Ohio.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Resident (6 months or longer) within the recruitment center

          -  Fulfillment of the criteria for spontaneous ICH

          -  No evidence of trauma, brain tumor/metastases or infectious processes as a cause of
             the hemorrhage

          -  Ability of the patient or legal representative to provide consent for an interview,
             blood pressure determinations and DNA sampling

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Woo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Osborne, RN, MSN</last_name>
    <phone>513-558-4241</phone>
    <email>jennifer.osborne@uc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Watson</last_name>
      <phone>410-706-1902</phone>
      <email>tiwatson@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Kittner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Kourkoulis</last_name>
      <phone>617-726-5358</phone>
    </contact>
    <investigator>
      <last_name>Jonathan R, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erlinda Yeh</last_name>
      <phone>919-681-4054</phone>
      <email>linda.yeh@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Michael L James, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jennifer Osborne</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Woo D, Sauerbeck LR, Kissela BM, Khoury JC, Szaflarski JP, Gebel J, Shukla R, Pancioli AM, Jauch EC, Menon AG, Deka R, Carrozzella JA, Moomaw CJ, Fontaine RN, Broderick JP. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke. 2002 May;33(5):1190-5.</citation>
    <PMID>11988589</PMID>
  </reference>
  <reference>
    <citation>Kissela BM, Sauerbeck L, Woo D, Khoury J, Carrozzella J, Pancioli A, Jauch E, Moomaw CJ, Shukla R, Gebel J, Fontaine R, Broderick J. Subarachnoid hemorrhage: a preventable disease with a heritable component. Stroke. 2002 May;33(5):1321-6.</citation>
    <PMID>11988610</PMID>
  </reference>
  <reference>
    <citation>Woo D, Kissela BM, Khoury JC, Sauerbeck LR, Haverbusch MA, Szaflarski JP, Gebel JM, Pancioli AM, Jauch EC, Schneider A, Kleindorfer D, Broderick JP. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke. 2004 Jun;35(6):1360-4. Epub 2004 Apr 15.</citation>
    <PMID>15087556</PMID>
  </reference>
  <reference>
    <citation>Woo D, Haverbusch M, Sekar P, Kissela B, Khoury J, Schneider A, Kleindorfer D, Szaflarski J, Pancioli A, Jauch E, Moomaw C, Sauerbeck L, Gebel J, Broderick J. Effect of untreated hypertension on hemorrhagic stroke. Stroke. 2004 Jul;35(7):1703-8. Epub 2004 May 20.</citation>
    <PMID>15155969</PMID>
  </reference>
  <reference>
    <citation>Flaherty ML, Woo D, Haverbusch M, Sekar P, Khoury J, Sauerbeck L, Moomaw CJ, Schneider A, Kissela B, Kleindorfer D, Broderick JP. Racial variations in location and risk of intracerebral hemorrhage. Stroke. 2005 May;36(5):934-7. Epub 2005 Mar 24.</citation>
    <PMID>15790947</PMID>
  </reference>
  <reference>
    <citation>Sauerbeck LR, Khoury JC, Woo D, Kissela BM, Moomaw CJ, Broderick JP. Smoking cessation after stroke: education and its effect on behavior. J Neurosci Nurs. 2005 Dec;37(6):316-9, 325.</citation>
    <PMID>16396084</PMID>
  </reference>
  <reference>
    <citation>Woo D, Kaushal R, Chakraborty R, Woo J, Haverbusch M, Sekar P, Kissela B, Pancioli A, Jauch E, Kleindorfer D, Flaherty M, Schneider A, Khatri P, Sauerbeck L, Khoury J, Deka R, Broderick J. Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage. Stroke. 2005 Sep;36(9):1874-9. Epub 2005 Aug 11.</citation>
    <PMID>16100021</PMID>
  </reference>
  <reference>
    <citation>Woo D, Sekar P, Chakraborty R, Haverbusch MA, Flaherty ML, Kissela BM, Kleindorfer D, Schneider A, Khoury J, Sauerbeck LR, Deka R, Broderick JP. Genetic epidemiology of intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2005 Nov-Dec;14(6):239-43.</citation>
    <PMID>16557295</PMID>
  </reference>
  <reference>
    <citation>Flaherty ML, Haverbusch M, Kissela B, Kleindorfer D, Schneider A, Sekar P, Moomaw CJ, Sauerbeck L, Broderick JP, Woo D. Perimesencephalic subarachnoid hemorrhage: incidence, risk factors, and outcome. J Stroke Cerebrovasc Dis. 2005 Nov-Dec;14(6):267-71.</citation>
    <PMID>16518463</PMID>
  </reference>
  <reference>
    <citation>Flaherty ML, Woo D, Haverbusch M, Moomaw CJ, Sekar P, Sauerbeck L, Kissela B, Kleindorfer D, Broderick JP. Potential applicability of recombinant factor VIIa for intracerebral hemorrhage. Stroke. 2005 Dec;36(12):2660-4. Epub 2005 Nov 3.</citation>
    <PMID>16269646</PMID>
  </reference>
  <reference>
    <citation>Woo D, Kaushal R, Kissela B, Sekar P, Wolujewicz M, Pal P, Alwell K, Haverbusch M, Ewing I, Miller R, Kleindorfer D, Flaherty M, Chakraborty R, Deka R, Broderick J. Association of Phosphodiesterase 4D with ischemic stroke: a population-based case-control study. Stroke. 2006 Feb;37(2):371-6. Epub 2005 Dec 22.</citation>
    <PMID>16373644</PMID>
  </reference>
  <reference>
    <citation>Flaherty ML, Haverbusch M, Sekar P, Kissela B, Kleindorfer D, Moomaw CJ, Sauerbeck L, Schneider A, Broderick JP, Woo D. Long-term mortality after intracerebral hemorrhage. Neurology. 2006 Apr 25;66(8):1182-6.</citation>
    <PMID>16636234</PMID>
  </reference>
  <reference>
    <citation>Flaherty ML, Haverbusch M, Sekar P, Kissela BM, Kleindorfer D, Moomaw CJ, Broderick JP, Woo D. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care. 2006;5(3):197-201.</citation>
    <PMID>17290088</PMID>
  </reference>
  <reference>
    <citation>Kaushal R, Pal P, Alwell K, Haverbusch M, Flaherty M, Moomaw C, Sekar P, Kissela B, Kleindorfer D, Chakraborty R, Broderick J, Deka R, Woo D. Association of ALOX5AP with ischemic stroke: a population-based case-control study. Hum Genet. 2007 Jun;121(5):601-7. Epub 2007 Mar 27.</citation>
    <PMID>17387518</PMID>
  </reference>
  <reference>
    <citation>Eden SV, Morgenstern LB, Sekar P, Moomaw CJ, Haverbusch M, Flaherty ML, Broderick JP, Woo D. The role of race in time to treatment after subarachnoid hemorrhage. Neurosurgery. 2007 May;60(5):837-43; discussion 837-43.</citation>
    <PMID>17460518</PMID>
  </reference>
  <reference>
    <citation>Kaushal R, Woo D, Pal P, Haverbusch M, Xi H, Moomaw C, Sekar P, Kissela B, Kleindorfer D, Flaherty M, Sauerbeck L, Chakraborty R, Broderick J, Deka R. Subarachnoid hemorrhage: tests of association with apolipoprotein E and elastin genes. BMC Med Genet. 2007 Jul 31;8:49.</citation>
    <PMID>17672902</PMID>
  </reference>
  <reference>
    <citation>Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007 Jan 9;68(2):116-21.</citation>
    <PMID>17210891</PMID>
  </reference>
  <reference>
    <citation>Kharofa J, Sekar P, Haverbusch M, Moomaw C, Flaherty M, Kissela B, Broderick J, Woo D. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 2007 Nov;38(11):3049-51. Epub 2007 Sep 27.</citation>
    <PMID>17901378</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2008</study_first_submitted>
  <study_first_submitted_qc>May 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2008</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Daniel Woo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>brain attack</keyword>
  <keyword>hemorrhagic stroke</keyword>
  <keyword>risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

